Cerevel Therapeutics Holdings Stock Z Score
| CERE Stock | USD 41.90 0.09 0.21% |
Cerevel | Z Score |
Cerevel Therapeutics Holdings Company Z Score Analysis
Cerevel Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Cerevel Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Cerevel Therapeutics is extremely important. It helps to project a fair market value of Cerevel Stock properly, considering its historical fundamentals such as Z Score. Since Cerevel Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cerevel Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cerevel Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Cerevel Therapeutics Holdings has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Cerevel Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cerevel Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cerevel Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cerevel Therapeutics' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 1.8 M | Eckert Corp | 2023-12-31 | 1.6 M | Baker Bros Advisors Lp | 2023-12-31 | 1.6 M | Alliancebernstein L.p. | 2023-12-31 | 1.1 M | Millennium Management Llc | 2023-12-31 | 1.1 M | Pentwater Capital Management Lp | 2023-12-31 | 1.1 M | Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | Magnetar Financial Llc | 2023-12-31 | 1 M | Cnh Partners, Llc | 2023-12-31 | 933.8 K | Bain Capital Investors Llc | 2023-12-31 | 65.7 M | Perceptive Advisors Llc | 2023-12-31 | 11 M |
Cerevel Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 7.11 B | ||||
| Shares Outstanding | 181.58 M | ||||
| Shares Owned By Insiders | 15.32 % | ||||
| Shares Owned By Institutions | 86.23 % | ||||
| Number Of Shares Shorted | 9.62 M | ||||
| Price To Earning | (0.26) X | ||||
| Price To Book | 11.28 X | ||||
| EBITDA | (441.64 M) | ||||
| Net Income | (432.84 M) | ||||
| Cash And Equivalents | 531.21 M | ||||
| Cash Per Share | 3.58 X | ||||
| Total Debt | 480.78 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 9.52 X | ||||
| Book Value Per Share | 3.71 X | ||||
| Cash Flow From Operations | (342.3 M) | ||||
| Short Ratio | 7.56 X | ||||
| Earnings Per Share | (2.67) X | ||||
| Target Price | 43.4 | ||||
| Number Of Employees | 334 | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 7.62 B | ||||
| Total Asset | 1.24 B | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 914.76 M | ||||
| Current Asset | 9.77 M | ||||
| Current Liabilities | 5.22 M | ||||
| Net Asset | 1.24 B |
About Cerevel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cerevel Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cerevel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cerevel Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cerevel Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cerevel Therapeutics' short interest history, or implied volatility extrapolated from Cerevel Therapeutics options trading.
Pair Trading with Cerevel Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cerevel Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cerevel Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Cerevel Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cerevel Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cerevel Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cerevel Therapeutics Holdings to buy it.
The correlation of Cerevel Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cerevel Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cerevel Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cerevel Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cerevel Therapeutics Piotroski F Score and Cerevel Therapeutics Valuation analysis. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Cerevel Stock analysis
When running Cerevel Therapeutics' price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.67) | Return On Assets (0.25) | Return On Equity (0.72) |
The market value of Cerevel Therapeutics is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cerevel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.